Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR-overexpressed colorectal cancer.
Sankha BhattacharyaVipan Kumar PariharNeeraj SinghKetan V HatwareAmit PageMayank SharmaMahendra Kumar PrajapatiAbhishek KanugoDatta M PawdeSaurabh MaruGirdhari Lal GuptaSunil KanvindePublished in: Nanomedicine (London, England) (2023)
Aims: Panitumumab (anti-Erb)-conjugated polycaprolactone (PCL) nanoparticles loaded with bosutinib (BTNB) were used to develop a targeted drug-delivery system for colon cancer cells. Materials & methods: Using carbodiimide coupling, anti-Erb was conjugated to BTNB-loaded PCL nanoparticles. Dynamic light scattering, scanning electron microscopy, transmission electron microscopy, Fourier-transform infrared spectroscopy, differential scanning calorimetry, x-ray diffraction and thermogravimetric analysis were used to analyze nanoparticles. Results: According to in vitro studies, anti-Erb-BTNB-PCL nanoparticles inhibited HCT116 cells more than BTNB alone. Cell arrest at different phases was examined for apoptotic potential. An in vivo efficacy study showed that anti-Erb-BTNB-PCL nanoparticles could target tumors selectively. Conclusion: Anti-Erb-conjugated BTNB nanoparticles could specifically target colon cancer.
Keyphrases
- electron microscopy
- small cell lung cancer
- walled carbon nanotubes
- cancer therapy
- high resolution
- epidermal growth factor receptor
- computed tomography
- drug delivery
- photodynamic therapy
- cell therapy
- stem cells
- risk assessment
- cell death
- cell cycle
- cell cycle arrest
- tyrosine kinase
- mesenchymal stem cells
- cell proliferation
- chronic myeloid leukemia
- dual energy